jaundice, in which oxidative hemolysis may play an important role, is more common among newborns with the A/A genotype than among those with the A/A genotype.

E. Bottini
F. Gloria Bottini
P. Borgiani
Cattedra di Pediatria Preventiva e Sociale Università di Roma “Tor Vergata”
L. Businco
Istituto di Clinica Pediatrica Università di Roma “La Sapienza”
Rome, Italy

REFERENCES

Autologous Stem Cell Transplantation: Exogenous Granulocyte Colony-Stimulating Factor or Granulocyte-Macrophage Colony-Stimulating Factor Modulate the Endogenous Cytokine Levels

To the Editor:

Autologous bone marrow (BM) and peripheral blood (PB) stem cell transplantation (SCT) is widely used in a variety of hematological malignancies and solid tumors. After high-dose conditioning therapy, the recovery of hematopoiesis is dependent on stem cell self-renewal and differentiation into lineage-committed progenitors, which undergo differentiation and maturation to morphologically recognizable precursors and terminal cells circulating in PB.

SCT is associated with absolute leukopenia before hematopoietic recovery. Administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF accelerates hematopoietic recovery. A number of investigators have detected elevated plasma G-CSF, GM-CSF, interleukin-3 (IL-3), M-CSF, IL-8 following myeloablation and marrow or PB progenitor cell transplantation. Time-course studies have demonstrated kinetic profiles that imply a relationship between cytokine levels and engraftment. In this context, we have previously shown that (1) G-CSF, IL-5, and IL-6 levels peak at the time of neutrophil nadir; (2) G-CSF, IL-8, and IL-6 levels directly correlate with maximum neutrophil counts. Hence, it was proposed that these three cytokines are coordinately secreted after SCT and mediate the production and activation of neutrophils. Finally, recent studies have provided evidence that accessory cells do not contribute to the production of endogenous cytokines released after SCT; in fact, patients transplanted with purified CD34+ cells release cytokines, including GM-CSF, IL-5, IL-8, and IL-3, at levels similar to those observed in patients transplanted with total PBMCs.

In the present study, the PBSC model has been analyzed to investigate (1) the influence of exogenous G-CSF/erythropoietin (Epo) and GM-CSF/Epo on the production of IL-3, GM-CSF, G-CSF, M-CSF, IL-8, and IL-6; (2) the relationship between IL-5 release and eosinophil response, and the effect of exogenous GM-CSF/Epo on the production of IL-5; and (3) the influence of exogenous G-CSF/Epo on the production of GM-CSF, IL-3, IL-5, IL-6, and IL-8.

Table 1: Ovarian Cancer Patients: Main Clinical Features, Infused Cells, and PBMC Recovery

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (years)</th>
<th>MNC (× 10⁶/kg)</th>
<th>CFU-GM (× 10⁶/kg)</th>
<th>PBMC Recovery</th>
<th>Platelets &gt;50 × 10⁹/L</th>
<th>Platelets &gt;0.5 × 10¹⁰/L</th>
<th>Platelets &gt;1 × 10¹⁰/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>35</td>
<td>11.7</td>
<td>40.3</td>
<td>10</td>
<td>10</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>36</td>
<td>7.3</td>
<td>59.2</td>
<td>11</td>
<td>12</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>38</td>
<td>13.0</td>
<td>67.2</td>
<td>9</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>35</td>
<td>9.2</td>
<td>19.4</td>
<td>10</td>
<td>10</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>47</td>
<td>8.9</td>
<td>19.2</td>
<td>11</td>
<td>11</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>44</td>
<td>5.8</td>
<td>46.1</td>
<td>11</td>
<td>11</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>43</td>
<td>7.8</td>
<td>130.1</td>
<td>7</td>
<td>7</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>57</td>
<td>6.1</td>
<td>36.0</td>
<td>8</td>
<td>8</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>47</td>
<td>7.9</td>
<td>51.9</td>
<td>8</td>
<td>8</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>54</td>
<td>6.9</td>
<td>18.6</td>
<td>9</td>
<td>9</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>36</td>
<td>7.7</td>
<td>22.3</td>
<td>10</td>
<td>10</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>46</td>
<td>8.4</td>
<td>35.5</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>54</td>
<td>5.4</td>
<td>12.5</td>
<td>8</td>
<td>8</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>44</td>
<td>4.5</td>
<td>44.0</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>44</td>
<td>7.0</td>
<td>46.2</td>
<td>8</td>
<td>7</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>56</td>
<td>1.7</td>
<td>33.2</td>
<td>9</td>
<td>9</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>40</td>
<td>6.7</td>
<td>45.1</td>
<td>9</td>
<td>8</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>55</td>
<td>5.0</td>
<td>N.V.</td>
<td>10</td>
<td>10</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>51</td>
<td>3.3</td>
<td>11.9</td>
<td>9</td>
<td>9</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>60</td>
<td>5.8</td>
<td>N.V.</td>
<td>10</td>
<td>9</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>57</td>
<td>5.1</td>
<td>N.V.</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

Patients 1 to 6 PBSCT
Patients 7 to 15 PBSCT + G-CSF/Epo
Patients 16 to 21 PBSCT + G-CSF/Epo
CSF and G-CSF on these parameters; and (3) the relationship of lactoferrin (Lf) plasma levels with the initial G-CSF peak and the subsequent neutrophil rescue. Modifications of plasma cytokine levels may be due to changes in production, release, consumption, or clearance. This clinical approach allows to establish temporal correlations between hematopoietic growth factor (HGF) administration and fluctuations of endogenous serum cytokines. However, the underlying cause/effect mechanisms remain largely hypothetical. Furthermore, because exogenous GM-CSF or G-CSF was combined with Epo, the specific role of each cytokine cannot be determined. Despite these limitations intrinsic to the clinical setting, the results provide novel information on the interaction between exogenous HGFs and the SCT-related cytokine release network.

We have also monitored the plasma concentrations of HGFs (i.e., IL-3, GM-CSF, G-CSF, Epo, IL-6, IL-8, and IL-5) and granule proteins (Lf and myeloperoxidase [Mpo]) in 21 ovarian cancer patients undergoing autologous PB SCT (Table 1).

G-CSF levels were markedly higher after exogenous G-CSF/Epo, as expected; furthermore, they were significantly lower following GM-CSF/Epo than after SCT alone; GM-CSF levels, moderately elevated after exogenous GM-CSF/Epo, were similar in the G-CSF/Epo and control groups. Finally, patients treated with either G-CSF/Epo or GM-CSF/Epo showed higher Epo plasma concentrations than the group receiving no exogenous HGFs (Fig 1 and data not shown).

When compared with SCT alone, (1) G-CSF/Epo treatment moderately increased the IL-3 level peaking at day +10, and did not significantly modify M-CSF level (data not shown), whereas it almost completely suppressed IL-8 and moderately decreased IL-6 and IL-5 levels (Fig 1); (2) GM-CSF/Epo treatment increased M-CSF, associated with a moderate increase of IL-3 levels peaking at day +10, moderately decreased both IL-5 and IL-8 concentration and did not modify IL-6 (Fig 1 and data not shown).

These observations indicate that exogenous G-CSF treatment induces a marked decrease of IL-8 levels and moderately decreased IL-6 concentrations, whereas exogenous GM-CSF markedly reduces G-CSF and IL-8 concentrations and increases M-CSF levels. The increase of IL-3 and the decrease of IL-5 levels were similarly observed in patients treated with G-CSF/Epo or GM-CSF/Epo.

Altogether, these results indicate that exogenous HGFs modulate endogenous cytokine levels; consideration of these aspects may contribute to optimize HGF treatment protocols in the clinical SCT setting.

We also evaluated the relationship between these phenomena and Lf release: (1) in all three groups the Lf concentration is strictly and directly correlated with the neutrophil response with respect to time-response patterns and plasma levels. (2) In patients subjected to SCT alone, the G-CSF decrease after the G-CSF peak coincides with initiation of the Lf response; the inverse correlation between these two parameters is highly significant (data not shown). Altogether, these temporal correlations after SCT provide circumstantial evi-
dence that, after the G-CSF peak, the generated granulocytes release Lf, which could negatively feedback on the release of G-CSF, thus in line with the experimental model proposed by Broxmeyer.13

ACKNOWLEDGMENT

We thank M. Fontana and C. Mastropietro for typing the manuscript, D. Marinelli for editorial assistance, and M. Teragnoli for graphics. This study was supported in part by CNR (ACRO Project, No. 95.00525.39, No. 95.00545.39), Rome and AIRC, Milan, Italy.

Ugo Testa
Robert Martucci
Department of Hematology and Oncology
Istituto Superiore di Sanità
Rome, Italy
Giovanni Scambia
Pierluigi Benedetti Panici
Salvatore Mancuso
Department of Gynecology
Catholic University
Antonio Camagna
G. Mastroberardino
Institute for Clinical Medicine (I, II)
University ‘La Sapienza’
Rome, Italy
Luca Pierrelli
Giacomo Menichella
Department of Hematology
Catholic University
Cesare Peschle
Department of Hematology and Oncology
Istituto Superiore di Sanità
Rome, Italy
Thomas Jefferson Cancer Institute
Thomas Jefferson University
Philadelphia, PA

REFERENCES

Autologous Stem Cell Transplantation: Exogenous Granulocyte Colony-Stimulating Factor or Granulocyte-Macrophage Colony-Stimulating Factor Modulate the Endogenous Cytokine Levels

Ugo Testa, Robert Martucci, Giovanni Scambia, Pierluigi Benedetti Panici, Salvatore Mancuso, Antonio Camagna, G. Mastroberardino, Luca Pierelli, Giacomo Menichella and Cesare Peschle